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AbsTRACT 
background change in the prevalence of asthma-like 
symptoms in populations of ageing adults is likely to be 
influenced by smoking, asthma treatment and atopy.
Methods the european community respiratory Health 
Survey collected information on prevalent asthma-like 
symptoms from representative samples of adults aged 
20–44 years (29 centres in 13 european countries 
and australia) at baseline and 10 and 20 years later 
(n=7844). net changes in symptom prevalence were 
determined using generalised estimating equations 
(accounting for non-response through inverse probability 
weighting), followed by meta-analysis of centre level 
estimates.
Findings Over 20 years the prevalence of ’wheeze’ and 
’wheeze in the absence of a cold’ decreased (−2.4%, 
95% ci −3.5 to −1.3%; −1.5%, 95% ci −2.4 to −0.6%, 
respectively) but the prevalence of asthma attacks, use 
of asthma medication and hay fever/nasal allergies 
increased (0.6%, 95% ci 0.1 to 1.11; 3.6%, 95% ci 3.0 
to 4.2; 2.7%, 95% ci 1.7 to 3.7). changes were similar 
in the first 10 years compared with the second 10 years, 
except for hay fever/nasal allergies (increase seen in the 
first 10 years only). Decreases in these wheeze-related 
symptoms were largely seen in the group who gave 
up smoking, and were seen in those who reported hay 
fever/nasal allergies at baseline.
Interpretation european adults born between 1946 
and 1970 have, over the last 20 years, experienced 
less wheeze, although they were more likely to report 
asthma attacks, use of asthma medication and hay fever. 
Decrease in wheeze is largely attributable to smoking 
cessation, rather than improved treatment of asthma. 
it may also be influenced by reductions in atopy with 
ageing.
bACkgRound
There are few population-based longitudinal studies 
which have described the evolution of the burden 
of respiratory symptoms and disease in popula-
tions of adults as they age. The European Commu-
nity Respiratory Health Survey II (ECRHS), a 
large multicentre, predominantly Western Euro-
pean, community-based study of younger adults 
reported that over a 10-year period (1992–2002) 
the prevalence of wheeze and wheeze-related symp-
toms fell among participants, while at the same time, 
the prevalence of asthma attacks and treatment for 
asthma increased.1 This pattern of change, which 
was seen in all participating countries, was hypoth-
esised as due to increased labelling (more ‘asthma’) 
and increased treatment (less wheeze) in those with 
relatively mild disease, possibly in response to the 
widespread adoption of guidelines for asthma treat-
ment during the 1990s.
At the time it seemed unlikely that the overall 
decrease in wheeze symptoms would be related to 
decreased atopy within the ageing populations, as 
there was a contemporaneous increase in the prev-
alence of self-reported nasal allergies, and little 
evidence of change in measured serum specific 
IgE in a representative subsample of responders.2 
The observed changes in symptom burden may 
have occurred in response to cessation of smoking 
with ageing,3–5 driven by improved tobacco control 
during the 1990s, but at the time of publication 
information on smoking habits of the study group 
was still unavailable.
key messages
What is the key question?
 ► Has the prevalence of asthma-like symptoms 
changed in populations of young adults as they 
have aged?
What is the bottom line?
 ► In young adults followed for 20 years, 
the prevalence of asthma, use of asthma 
medication and self-reported hay fever/allergic 
rhinitis has increased, although, largely related 
to smoking cessation, the prevalence of wheeze 
has fallen.
Why read on?
 ► This prospective survey which includes 
follow-up data on adults collected over the 
last 20 years provides unique European-wide 
information on the evolution of asthma-like 
symptoms in adults as they have aged.
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The ECRHS has now completed the 20-year follow-up of 
participants (ECRHS III). Here we describe changes in the 
prevalence of respiratory symptoms in these adults over the 
20-year follow-up period and assess whether observed changes 
in symptom prevalence are likely to be related to changes in use 
of asthma medication, changes in a proxy marker for allergy (the 
presence of nasal allergies) or changes in smoking behaviour. We 
report our findings adhering to the Standards for Reporting of 
Observational Epidemiology.
MeThods
In 1990–1992, forty-eight participating centres (mainly, but not 
only, in Western Europe) each selected an area with a popula-
tion of at least 150 000 people. At least 1500 men and 1500 
women aged 20–44 years were selected at random from a popu-
lation-based sampling frame, and sent a questionnaire asking 
about symptoms and attacks of asthma in the last 12 months, 
current use of asthma medication and presence of nasal aller-
gies including hay fever. A random sample of responders to this 
survey was invited for further tests, including an extended inter-
viewer administered questionnaire and lung function tests.6
In 2000–2002, twenty-nine (of the original 48) centres (14 
countries) sent the identical brief questionnaire to all individ-
uals who had taken part in the clinical assessment. The methods 
and the results1 7–9 have been presented in full elsewhere. In 
Melbourne the target sample answered identical questions 
through interviewer administered questionnaire, and in Spain 
(five centres) questions on hay fever/nasal allergies were admin-
istered separately by interviewer questionnaire.
From 2008 to 2013, these 29 centres (28 in Europe and 1 in 
Australia) sent the identical questionnaire to all responders to 
the postal survey in ECRHS II (Spanish centres; target popu-
lation consisted of responders to clinical assessment ECRHS 
II). In centres where administrative records were available, 
Data Protection legislation permitted and ethical approval was 
granted, the questionnaire was also sent to those who were 
eligible for ECRHS II but had not taken part at the time of 
ECRHS II.
Information on smoking was collected during clinical assess-
ment in ECRHS I and ECRHS II, and from the postal survey in 
ECRHS III. In 26 centres information on chronic winter cough 
and chronic winter phlegm was collected from the subsample 
of responders to the clinical assessments at each phase of the 
survey (chronic cough/phlegm for ‘most days for as much as 
three months each year’ in the winter).
The relevant questions in the postal survey are shown in online 
supplementary appendix 1.
The study flow is described in figure 1.
sTATIsTICAl MeThods
Absolute (‘net’) change in symptoms per 10 years of follow-up 
in those who responded to all three surveys was estimated using 
a logistic generalised estimating equations (GEE) model, with 
exchangeable correlation and Huber variances.10 As length of 
follow-up varied between centres, a quadratic reference spline 
was used11 to estimate the prevalence of symptoms in each popu-
lation on 1 January 1991, 1 January 2001 and 1 January 2011. 
Analyses were conducted within centre and estimates combined 
Figure 1 Study flow diagram for participants in the ECRHS III Canada (6) and Poland (1) not included—first data submitted after 1995. 
Note that ECRHS included follow-up of non-random sample of those selected because they had symptoms—this group is not included in this 
analysis. ECRHS, European Community Respiratory Health Survey.
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using random effects meta-analysis12 and the I2 statistic13 used to 
assess heterogeneity between centres.
To adjust for non-response, analyses were conducted using 
inverse response-propensity weights14 in which ‘response’ was 
defined as ‘responded to all 3 surveys,’ and response odds deter-
mined multiplicatively (using separate logistic regressions in each 
centre) by age, gender, smoking status (never, ex, current) and 
reporting of wheeze in ECRHS I. Estimates from these adjusted 
analyses are presented.
Further analyses were stratified by gender (male or female), by 
age group at ECRHS I (<35 and 35+ years), by use of asthma 
treatments over the whole study period (never, ever), four 
smoking groups (non-smoker throughout period of follow-up, 
smokers at baseline who gave up during follow-up, smokers 
throughout follow-up and ex-smokers at follow-up with variable 
smoking history during the study) and presence of hay fever/
nasal allergies at baseline.
Statistical analysis was carried out using Stata.15
ResulTs
Response
Table 1 shows, by centre, the number of participants in the 
target sample (responders to the ECRHS I clinical survey), the 
number who responded to ECRHS II, and of these, the number 
who responded to ECRHS III. Overall, 53.2% (n=7884) of 
participants in the target sample completed all three question-
naires over the 20-year period, and 950 (6.42%) completed 
the questionnaire in ECRHS I and ECRHS III only. Response 
to all three questionnaires varied by centre (nine centres with 
response >60% and four centres less than 40%). The mean age at 
follow-up was 53.0 years with some variation in age at follow-up 
between centres, explained by a later start in ECRHS I in some 
centres (eg, Tartu, Estonia). Response to all three surveys was 
Figure 2 Net change in prevalence (%) of ‘current use of asthma medication’ (prevalence at ECRHS III minus prevalence at ECRHS I) adjusted 
for non-response and estimated by generalised estimating equations No estimate for Melbourne, Australia or Basel, Switzerland, as information on 
asthma medication use was not recorded during postal survey. ECRHS, European Community Respiratory Health Survey.
Figure 3 Comparison of change in prevalence in first 10 years to 
change in prevalence in second 10 years of follow-up (ie, ECRHS III-II 
change in prevalence minus ECRHS II-I change in prevalence) for all 
symptoms: adjusted for non-response and estimated by generalised 
estimating equations. ECRHS, European Community Respiratory Health 
Survey.
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strongly related to being older, a female, a non-smoker and not 
having wheeze at baseline. Response rates were similar in those 
with and without diagnosed asthma (those reporting ‘asthma 
attack’ or ‘current asthma treatment’).
Change in respiratory symptoms
Table 2 shows the absolute (or ‘net’) change in respiratory symp-
toms adjusted for non-response during follow-up. The crude 
prevalences and non-response-adjusted prevalences at baseline 
are shown. It is the latter on which the change estimates are 
based. For most, but not all symptoms, adjusted estimates were 
marginally lower than the crude prevalence, reflecting the higher 
propensity for healthier subjects to respond to repeat postal 
surveys
Over the 20-year period, the 12-month period prevalence of 
wheeze and wheeze in the absence of a cold fell (net change in 
prevalence −2.4%, 95% CI −3.5 to −1.3 and −1.5%, 95% CI 
−2.4 to −0.6%, respectively). There was no change in the 
prevalence of ‘wheeze with breathlessness,’ but there was a net 
increase in the prevalence of asthma attacks, current use of treat-
ments for asthma (see figure 2) and current hay fever/nasal aller-
gies. These observations were consistent across all centres (all 
pheterogeneity>0.5, all I
2=0).
For the other asthma-like symptoms (waking with chest 
tightness, being woken by shortness of breath, being woken by 
coughing) the direction and magnitude of prevalence changes 
varied between centres (pheterogeneity<0.01, I
2>50) with no 
obvious or consistent geographical pattern (see online supple-
mentary figure E1a, E1b, E1c). Among the participants who 
completed the clinical survey at each of the three surveys and 
provided information on symptoms of chronic bronchitis, there 
were non-significant small increases in the prevalence of chronic 
winter cough and chronic winter phlegm with some variation 
between centres (pheterogeneity=0.0027 and 0.019, respectively; 
I249.1% and 40.1%, respectively: see online supplementary 
figure E1d, E1e).
Changes in symptom prevalence in the first 10 years of 
follow-up were broadly similar to the changes that were seen in 
the second 10 years of follow-up (p>0.05, see figure 3), except 
for hay fever/nasal allergies (increases largely seen in the first, 
but not the second, 10 years of follow-up) and chronic winter 
cough (where the opposite was seen).
Change in symptoms by age, gender, smoking history, 
treatment use and atopy
Table 3 shows net changes in the prevalence of wheeze, asthma 
attacks, use of asthma medication and hay fever/nasal allergies 
(ie, the symptoms that showed consistent patterns of change 
across all centres) in specific subgroups of the population.
Compared with men, women showed smaller decreases in 
wheeze symptoms and larger increases in use of asthma medi-
cation and hay fever/nasal allergies, although the 95% CIs over-
lapped (eg, net decrease in prevalence of wheeze in men −2.6%, 
95% CI −4.2 to −1.1; in women −1.9%, 95% CI −3.6 to −0.3: 
net increase in prevalence of current use of asthma medication 
in men 2.5%, 95% CI 1.7 to 3.4; in women 3.9%, 95% CI 2.8 
to 5.0). Changes were unrelated to age at the start of the study, 
except for hay fever/nasal allergies where net increases were 
greater in those who were younger at baseline (as has been noted 
at the 10-year follow-up1).
The pattern of change in prevalence of wheeze differed by 
the proxy marker for atopy (reporting of hay fever/nasal aller-
gies at baseline), with greater decreases being seen in those 
with hay fever/nasal allergies. Net increases in the prevalence 
of asthma attacks occurred among those who did not have 
hay fever/nasal allergies at baseline (1.2%, 95% CI 0.8 to 1.7, 
p=1.6×10−7) and small net decreases, just below conventional 
levels of significance (−1.5%, 95% CI −3.1 to 0.1, p=0.066) 
occurred in those who did.
During the first 10 years of follow-up the prevalence of 
smoking decreased (information collected during clinical inter-
view16). It fell further during the second 10 years of follow-up 
with much larger decreases seen in some countries compared 
with others (net change in prevalence of active smoking over 20 
years, −16.6%; 95% CI −20.3 to −12.9%; I2=89.9%; Pheteroge-
neity=5.0×10
−40; greatest change in Reykjavik, Iceland −37.1%, 
95% CI −42.6 to −31.6%; least change in Basel, Switzerland 
−2.0%, 95% CI −4.7% to 0.8%) (figure 4). Larger net decreases 
in prevalence of wheeze, and wheeze in the absence of a cold, 
occurred among those who gave up smoking during the period 
of the study (figure 5), with a similar pattern of change for 
chronic winter cough and chronic winter phlegm. Changes in 
the prevalence of asthma attacks, use of asthma medication and 
of hay fever/nasal allergies were similar irrespective of smoking 
history.
There was no evidence that those who received asthma treat-
ment at some point during follow-up had greater decreases in 
the prevalence of wheeze than those who did not receive treat-
ment. The net increase in asthma attacks (and in chronic winter 
cough and phlegm) occurred almost exclusively among those 
who had received asthma medication (shown in figure 6, which 
includes net changes in all symptoms).
dIsCussIon
Adults taking part in the ECRHS, an international multicentre 
cohort study, were less likely to report most non-specific respi-
ratory symptoms (predominantly wheeze) as they aged over a 
period of 20 years, even though, in the same populations at 
the same time, there were marked increases in asthma, use of 
asthma medication and hay fever/nasal allergies. This decrease in 
wheeze symptoms at a group level, which was only seen in those 
who had never been treated for asthma, is most likely explained 
by the fall in active smoking as the cohorts have grown older. 
Changes in atopy may also have had an impact on the natural 
history of wheeze.
Information on the changing prevalence of symptoms 
in populations of adults as they age has been limited by the 
relative paucity of large cohort studies of adults with detailed 
repeat information on respiratory symptoms. The prevalence 
of wheeze, cough and phlegm increased in 900 Canadian adults 
aged 20–69 years followed for 10 years (1993–2003).17 Over a 
similar period, the prevalence of respiratory symptoms (wheeze, 
cough and asthma) increased in 1000 young (aged 16–34 years) 
English adults,18 and in Northern Italy the prevalence of asthma, 
allergic rhinitis and phlegm increased in about 800 participants 
followed for 25 years.19 In contrast, the Study of Health in 
Pomerania (SHIP)  study (in Germany) followed 3000 adults, 
aged 20–79 years, for about 6 years (1997/2001–2003/2006) 
and the prevalence of wheeze, waking with chest tightness 
and waking with shortness of breath fell (−0.7%, −1.9% and 
−1.0%, respectively) with some decrease in the prevalence 
of smoking (from 27.9% to 25.9%).20 Cohort studies such as 
SHIP20 and others in the UK,21 Norway22 and Chile23 show that 
change in the prevalence of respiratory symptoms is strongly 
determined by smoking uptake and smoking cessation patterns 
in the study populations.
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In line with this, the most striking changes in respiratory 
symptom prevalence were seen in those who gave up smoking. 
Decreases in smoking within the cohort reflect changes in adult 
smoking rates that have occurred in Europe and elsewhere over 
the last years,24 but the link between decreases in smoking and 
decreases in symptoms has not always been demonstrated in 
studies using repeat cross-sectional data, rather than longitu-
dinal data. Against a background of falling smoking rates, cross–
sectional studies report the prevalence of respiratory symptoms 
to have decreased,25–27 been stable28 29 or increased.30–32
The ECRHS covers a longer time period (20 years) than most 
respiratory cohorts and has information from three follow-ups 
in populations with widely differing prevalences of respiratory 
symptoms, asthma and smoking cessation. There was a net 
increase in asthma attacks and use of asthma treatment (and 
hay fever/nasal allergies) over the last 20 years in all participating 
centres. This increase has occurred among those who have 
received treatment during the period of the study, reflecting both 
treatment in response to the development of asthma and possibly 
increasing severity of disease during the period of follow-up. 
From our data, there is no evidence that the population level net 
Figure 4 Net change in prevalence (%) of ‘current smoking’ 
(prevalence at ECRHS III minus prevalence at ECRHS I); adjusted for non-
response and estimated by generalised estimating equations in each 
centre. ECRHS, European Community Respiratory Health Survey.
Figure 5 Net change in prevalence (%) of symptoms (prevalence at ECRHS III minus prevalence at ECRHS I); adjusted for non-response and 
estimated by generalised estimating equations stratified by smoking history. Some differences in numbers of countries for each analysis occur as 
information on smoking history in some centres differed. ECRHS, European Community Respiratory Health Survey.
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decrease in wheeze can be attributed to the more widespread use 
of asthma medication. The information on medication usage in 
this postal survey is too limited to determine whether people with 
asthma taking continuous regular daily medication (in particular 
inhaled steroids) throughout follow-up have become less symp-
tomatic or showed slower disease progression compared with 
those who have taken little or irregular medication. Patients who 
adhere to regular treatment are likely to enjoy the best results 
but ‘regular treatment’ is not regular in most patients and main-
tenance treatment in real life should be assumed in most patients 
to be intermittent and symptom driven.33
Of interest we show that net decreases in wheeze symptoms 
are greater in those with hay fever/nasal allergies at baseline. 
In a representative subsample of ECRHS III responders there 
has been a decrease in serum-specific IgE sensitisation—partic-
ularly to house dust mite and cat.34 There was less evidence 
for decreases in sensitisation to grass, and, consistent with this, 
here we show substantial net increases in the prevalence of 
self-reported hay fever/nasal allergies. Possible interpretations 
of our observations include (1) some of those with symptoms 
of hay fever/nasal allergies at baseline have become less atopic 
with fewer wheeze symptoms and (2) those with hay fever/nasal 
allergies at baseline have received effective treatment of their 
nasal disorder leading to improvement in respiratory symptoms. 
Our findings are not contradictory with earlier observations 
from ECRHS35 showing that hay fever is a risk factor for new 
asthma onset, but may reflect a lower burden of wheeze symp-
toms in those with hay fever/nasal allergies as they grow older.
Further investigation of these observations is planned within 
the ECRHS sample with detailed clinical information, treat-
ment information and serial measures of sensitisation (n~3500). 
Such analysis will be complicated by increases in the prev-
alence of hay fever/nasal allergies being greater in those born 
more recently. We observed this at the 10-year follow-up and 
it is consistent with the observation of cohort-related increases 
in the prevalence of serum-specific IgE to grass pollen within 
the ECRHS cohort.34 Furthermore, our observations need to be 
considered using all the information available from the clinical 
evaluations, and taking into account the full range of respira-
tory symptoms. In this report we have reported some data from 
these clinical interviews that demonstrate non-significant small 
increases in the prevalence of chronic winter cough and chronic 
winter phlegm of much lower magnitude than the increases in 
prevalence of asthma attacks or use of medication.
Figure 6 Net change in prevalence (%) of symptoms (prevalence at ECRHS III minus prevalence at ECRHS I); adjusted for non-response and 
estimated by generalised estimating equations stratified by use of asthma medication. ECRHS, European Community Respiratory Health Survey.
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As with all cohorts, the ECRHS has some evidence of system-
atic loss to follow-up. We have used weighting procedures to 
account for non-response and our main observations are consis-
tently seen across all centres irrespective of underlying response 
rates. It seems unlikely that systematic bias in loss to follow-up 
can account for the patterns we observed.
We have focused on changes in prevalence rather than present 
incidence and remission rates. The prevalence of disease is of 
direct relevance when assessing the burden of chronic disease in 
populations. Furthermore, incidence and remission rates can be 
biased by measurement error at both baseline and at follow-up, 
with an unknown proportion of study participants reporting 
symptoms when they do not have them (false positives) or 
denying symptoms when they do (false negatives). Even if rela-
tively small, this measurement error can lead to erroneously high 
incidence and remission rate.36 Therefore, we have used GEE to 
derive changes in population prevalence of symptoms/disease as 
we have done in previous work1 and others have done when 
working with similar respiratory symptom data.19 20 23
Our report is using information derived from a postal survey 
on a large sample of adult and information on other relevant 
determinants of changes in the prevalence of respiratory symp-
toms (eg, body mass index) is not available. Analyses using infor-
mation from detailed clinical assessment and incorporating other 
risk factors are in progress, but inevitably will be based on a 
smaller number of participants.
In conclusion, our study suggests that over the last 20 years, 
European adults born between 1946 and 1970, who have grown 
older over the last 20 years, have reduced their smoking and 
report fewer wheeze-related symptoms. Over the same period, 
the prevalence of asthma attacks, use of medication for asthma 
and hay fever/nasal allergies has risen. At a population level, the 
net decreases in symptoms are explained by smoking cessation. 
We cannot rule out that changes in atopy with ageing may have 
also contributed to these decreases.
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